Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older

Nephrology Dialysis Transplantation

Volumn 24, Issue 10, 2009, Pages 3138-3143

  Ibrahim, Hassan N ^a,b   Ishani, Areef ^a,b,c   Guo, Haifeng ^a   Gilbertson, David T ^a  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chronic kidney disease; Erythropoiesis stimulating agents; Transfusions

Indexed keywords

ANTIANEMIC AGENT; IRON;

AGED; ANEMIA; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HEALTH SERVICE; HEART ARRHYTHMIA; HOSPITALIZATION; HUMAN; HYPERTENSION; INTERNATIONAL CLASSIFICATION OF DISEASES; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICARE; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ANEMIA; BLOOD TRANSFUSION; CHRONIC DISEASE; COHORT STUDIES; HEMATINICS; HUMANS; KIDNEY DISEASES; RETROSPECTIVE STUDIES;

EID: 70349482089     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp213     Document Type: Article

References (11)

1. Higgins MR, Grace M, Ulan RA et al. Anemia in hemodialysis patients. Arch Intern Med 1977; 137: 172-176
2. Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med 1997; 336: 933-938
3. Jones M, Ibels L, Schenkel B et al. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 2004; 65: 757-767
4. Ross SD, Fahrbach K, Frame D et al. The effectofanemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther 2003; 25: 1786-1805
5. Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 1989; 14(Suppl 1): 14-18
6. Beusterien KM, Nissenson AR, Port FK et al. The effects of re-combinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 7: 763-773
7. Ibrahim H, Ishani A, Foley RN et al. Temporal trends in red blood transfusions among US dialysis patients, 1992-2005. Am J Kidney Dis 2008; 52: 1115-1121
8. Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 2003; 17: 120-162
9. Hakim RM, Stivelman JC, Schulman G et al. Iron overload and mobilization in long-term hemodialysis patients. Am J Kidney Dis 1987; 10: 293-299
10. Cardarelli F, Pascual M, Tolkoff-Rubin N et al. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int 2005; 18: 532-540
11. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590